Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06635408
NCT06635408CompletedNot Applicable

Cystatin c as a Predictive Biomarker of Acute Kidney Injury and Neurological Outcomes in Aneurysmal Subarachnoid Haemorrhage Patients

Alexandria University1 site in 1 country52 target enrollmentStarted: October 30, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
52
Locations
1
Primary Endpoint
Acute kidney injury
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is:

  • Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?

Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patient admission to hospital within 48 hours of subarachnoid haemorrhage onset.
  • •Subarachnoid haemorrhage caused by intracranial aneurysm rupture and is confirmed via computed tomography angiography (CTA).
  • •Medical treatment, microsurgical clipping, or interventional endovascular treatment of aneurysm is performed within 48 hours of subarachnoid haemorrhage onset.

Exclusion Criteria

  • •Prior onset of subarachnoid haemorrhage or other neurological diseases such as ischemic stroke, hemorrhagic stroke, or severe head trauma.
  • •Systemic diseases, such as chronic liver diseases, chronic lung diseases, chronic heart failure, thyroid diseases and cancer.
  • •Renal impairment at time of admission (creatinine-based eGFR less than 60 ml/min per 1.73 m2 body surface area).
  • •Patients who are hemodynamically unstable at time of admission.
  • •Mortality within 10 days after admission (duration of study).

Outcomes

Primary Outcomes

Acute kidney injury

Time Frame: 6 days

stages "risk" and "injury" are considered early AKI

Secondary Outcomes

  • Adverse neurological outcomes(10 days all except mortality within 28 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Ayman

principle investigator

Alexandria University

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary InterventionAcute Kidney Injury
NCT06459362Assiut University45
Unknown
Not Applicable
Plasma Cystatin C and Acute Kidney InjuryAcute Kidney Injury
NCT01652755Jinhua Central Hospital100
Unknown
Not Applicable
Acute Kidney Injury in Newborns With Perinatal AsphyxiaAcute Kidney Injury
NCT03617055Assiut University50
Completed
Not Applicable
Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With SepsisAcute Kidney Injury
NCT03097393Benha University67
Not yet recruiting
Not Applicable
To detect serum cystatin C levels in postoperative exploratory laparotomy patients who are admitted in intensive care unit to find out acute kidney injury
CTRI/2021/04/032778Department of Anaesthesia GMCH Chandigarh